Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market

Core Viewpoint - Orion Corporation has entered into an agreement with Shilpa Medicare to commercialize Recombinant Human Albumin in the European market, enhancing its portfolio in hospital generics [1][2][3] Group 1: Agreement Details - Orion will have exclusive rights to distribute, market, and sell Shilpa's Recombinant Human Albumin in Europe [2] - Shilpa will receive development and regulatory milestone payments from Orion as part of the agreement [2] Group 2: Strategic Importance - The partnership is aimed at strengthening Orion's strategy in value-added hospital generics and expanding its offerings in Europe [3] - Shilpa views this collaboration as a significant step in delivering innovative recombinant products to patients and enhancing its presence in regulated markets [3] Group 3: Company Background - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals [4] - In 2024, Orion's net sales reached EUR 1,542 million, employing approximately 3,700 professionals globally [4]